17 results about "Elastin like polypeptides" patented technology

The invention relates to genetically encoded fusion proteins comprised of a capture component that binds a target with high affinity and a peptide polymer, such as elastin-like polypeptides, that display phase behavior and can be used for purification. The invention further relates to methods for optimizing capture fusion proteins for individual biologic targets such that phase separation occurs under desirable conditions, such as at room temperature, lower concentrations of salt, and / or at suitable pH ranges and optimized capture domains and polypeptides with phase behavior that have been identified by the optimization methods.

The invention relates to the technical field of biological materials, in particular to composite hydrogel as well as a preparation method and application thereof. In particular to an ion response type ELPs-SA composite hydrogel constructed based on elastin-like polypeptides (ELPs) and sodium alginate (SA) as well as a preparation method and application of the ion response type ELPs-SA composite hydrogel. According to the hydrogel, elastic-like polypeptides ELP-Vs (such as adhesion promotion, angiogenesis, antibiosis and the like) with biological functions are introduced and react with SA, CaCO3 and gluconolactone (GDL) together, and the non-covalent cross-linked three-dimensional network hydrogel is formed under mild conditions. The obtained hydrogel has excellent mechanical strength (the energy storage modulus is 450-1773 Pa), a proper microporous structure (the pore diameter is 50-100 microns) and good biocompatibility, and can support three-dimensional culture of cells and promote angiogenesis and immunoregulation. The material has a wide application prospect in the biomedical fields of tissue engineering, wound repair, organoid construction and the like.

This invention relates to protein-based adhesives that are capable to adhere to a substrate in a dry, wet, moist, or an aqueous environment. Particularly, said adhesives comprise a crosslinking agent and an elastin-like polypeptide (ELP) that contain tyrosine, lysine, cysteine, dihydroxyphenylalanine (DOPA) or trihydroxyphenylalanine (TOPA) amino acid residue, or a combination thereof, on the polypeptide chain of said ELP. Among others, the adhesives disclosed herein may find broad applications in medical treatments and surgical operations. Compositions and methods of use are within the scope of this application.

The invention provides a biological membrane fusion nano-micelle, a drug-loaded biological membrane fusion nano-micelle as well as a preparation method and application thereof, and belongs to the technical field of medicines. The biological membrane fusion nano-micelle comprises an elastin-like polypeptide nano-micelle, a cancer cell membrane coating the surface of the elastin-like polypeptide nano-micelle, L-arginine located between the elastin-like polypeptide nano-micelle and the cancer cell membrane, and a fat-soluble photosensitizer located between phospholipid bilayers of the cancer cell membrane. The biological membrane fusion nano-micelle can bypass a traditional endocytosis way, and the treatment effect can be improved; the hydrophilic and hydrophobic structure of the elastin-like polypeptide nano-micelle is utilized to facilitate encapsulation of fat-soluble chemotherapeutic drugs (such as rapamycin or adriamycin), and a fat-soluble photosensitizer (such as a photosensitizer IR780 or a photosensitizer ICG) can be embedded into a phospholipid bilayer of a cancer cell membrane by utilizing the hydrophobic effect of the elastin-like polypeptide nano-micelle. Cancer synergistic chemotherapy, photodynamic therapy and gas therapy can be realized.

The present invention relates to the preparation of a recombinant protein based on an elastin-like polypeptide and an animal cell expression platform thereof, and specifically relates to an animal cell expression platform using a fusion recombinant protein comprising: a repetitive elastin-based polypeptide (EBPn, where n represents the number of repetitive base units of EBP); and an antibody constant region (Fc) linked to the EBPn; the present invention relates to an EBPn-Fc recombinant protein animal cell expression platform and, more specifically, to a technology for an EBPn-Fc recombinant protein animal cell expression platform capable of fusing various proteins, including peptides, proteins or antibody fragments, on the front and rear sides of EBPn-Fc or on the front and rear sides of EBPn-Fc. In the EBPn-Fc animal cell expression platform, a protein (such as a peptide, a protein, an antibody fragment and the like) is expressed in a form fused with EBPn-Fc, so that high-purity purification can be realized, and a nanostructure can be formed while the function of the fusion protein is maintained. Therefore, the EBPn-Fc animal cell expression platform can be used for research and treatment application of recombinant protein.

This invention relates to protein-based adhesives that are capable to adhere to a substrate in a dry, wet, moist, or an aqueous environment. Particularly, said adhesives comprise a crosslinking agent and an elastin-like polypeptide (ELP) that contain tyrosine, lysine, cysteine, dihydroxyphenylalanine (DOPA) or trihydroxyphenylalanine (TOPA) amino acid residue, or a combination thereof, on the polypeptide chain of said ELP. Among others, the adhesives disclosed herein may find broad applications in medical treatments and surgical operations. Compositions and methods of use are within the scope of this application.

The invention relates to an elastin-like polypeptide-based composite material and a cell membrane bionic elastin-like polypeptide-based nano-drug. After the nano-drug is injected into the body of a mouse through caudal vein, the nano-drug can be promoted to cross a blood brain barrier to enter in-situ brain glioma, meanwhile, MR imaging, chemical kinetic treatment and sonodynamic treatment of tumors are achieved, and by activating a cGAS-STING pathway, immunogenic cell death is caused to activate anti-tumor immune response, so that the anti-tumor effect is achieved. The obvious anti-tumor effect and the potential clinical application value are realized.

A composition including an elastin-like polypeptide (ELP) coupled to a kidney targeting peptide and a therapeutic agent is provided.

A bioconjugate including a photosensitizer unit, in particular a phthalocyanine unit, and an elastin-like polypeptide conjugated thereto, the elastin-like polypeptide containing at least one occurrence of a monomeric unit having the formula Xaa1PXaa2Xaa3G, wherein P represents a prolyl residue, G represents a glycyl residue, Xaa2 represents a glycyl residue or an alanyl residue and either Xaa1 represents a valyl residue and Xaa3 represents a sulfur-containing amino acid residue having a side chain of formula —(CH2)z—S—R′ or Xaa3 represents a valyl residue and Xaa1 represents a sulfur-containing amino acid residue having a side chain of formula —(CH2)z—S—R′. This bioconjugate proves particularly useful for the treatment of diseases by photodynamic therapy.

Disclosed herein are methods, pharmaceutical compositions, and kits for image-guided brachytherapy. An example method includes navigating a hollow tube to a tumor in a subject using an imaging modality and administering a pharmaceutical composition through the hollow tube to the tumor. An example pharmaceutical composition includes a pharmaceutically acceptable excipient and a collection of self-assembling conjugates, each self-assembling conjugate including a radionuclide coupled to an elastin-like polypeptide, the collection of self-assembling conjugates being included in the pharmaceutical composition at a concentration of no more than 300 µM.

The present disclosure provides isothermally phase-separable elastin-like polypeptides (ELPs), the ELPs comprising: i) a first ELP domain having a first lower critical solution temperature (LCST); and ii) a second ELP domain having a second LCST that is different from the first LCST, wherein the first and second ELP domains are separated by an enzymatic cleavage site. Also included in the present disclosure are conjugates of the subject ELPs, nucleic acids encoding the subject ELPs, cells comprising nucleic acids encoding the subject ELPs, methods of use for the subject ELPs, and related kits.

Disclosed herein are fusion proteins comprising a biologic and an elastin‑like polypeptide (ELP) attached to the biologic that is capable of being expressed and secreted from a eukaryotic cell. Also disclosed herein are methods for producing the biologic-based fusion protein.

This disclosure provides a novel compositions and methods to deliver cyclosporine A using genetically engineered protein polymers.

A composition and method of using the composition to treat neurological disorders including Alzheimer's disease are disclosed wherein the composition includes an elastin-like polypeptide (ELP) and a drug. The ELP undergoes a transition from a solution phase to a gel phase as the temperature is raised above a transition temperature, and in doing so sequesters at least a portion of the drug into the gel phase. The composition is configured such that intranasal delivery of the composition results in gelation and sequestration of the drug by the ELP, thereby allowing the drug to traverse olfactory mucosa into brain tissue in order to treat neurological disorders, including Alzheimer's disease.

This invention provides a material that utilizes the self-healing properties and / or high bioadhesion of elastin-like peptides. A composition comprising: (Sequence No. 1: X) 1 GGX 2 G) n The G-sequence blocks formed (where X) 1 Same or different, indicating V or L, X 2 Same or different, representing V or L, n represents an integer greater than 4. ) and by (Sequence number 2: VPGX 3 G) m The P-sequence block formed (where X) 3 ) represents any amino acid that is the same or different, and m represents an integer greater than 5. ) elastin-like block peptide sequences and polypeptides having amino groups, and water-soluble polymers having aldehyde groups.

Methods and pharmaceutical compositions for delivering a therapeutic agent, treating a neovascularization disorder, and treating an ocular infection include make use of a compound that includes an elastin-like polypeptide (ELP) coupled to a therapeutic agent, wherein the ELP comprises at least one repeat of the amino acid sequence VPGXG (SEQ ID NO: 1), and where the composition is suitable for ocular administration.